{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:36:28Z","timestamp":1780439788904,"version":"3.54.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00105-024-05400-0","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T13:02:15Z","timestamp":1727787735000},"page":"889-901","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Aktuelles zu Impfungen und Immunisierungsstrategien in der Dermatologie","Current vaccination and immunization strategies in dermatology"],"prefix":"10.1007","volume":"75","author":[{"given":"Steffen","family":"Schrenker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luise","family":"Erpenbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"key":"5400_CR1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.7326\/0003-4819-127-8_part_1-199710150-00010","volume":"127","author":"N Barquet","year":"1997","unstructured":"Barquet\u00a0N, Smallpox\u00a0DP (1997) the triumph over the most terrible of the ministers of death. Ann Intern Med 127:635\u2013642. https:\/\/doi.org\/10.7326\/0003-4819-127-8_part_1-199710150-00010","journal-title":"Ann Intern Med"},{"key":"5400_CR2","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena\u00a0M, van der Burg\u00a0SH, Melief\u00a0CJM et\u00a0al (2021) Therapeutic cancer vaccines. Nat Rev Cancer 21:360\u2013378. https:\/\/doi.org\/10.1038\/s41568-021-00346-0","journal-title":"Nat Rev Cancer"},{"key":"5400_CR3","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/s0091-6749(98)70271-4","volume":"102","author":"J Bousquet","year":"1998","unstructured":"Bousquet\u00a0J, Lockey\u00a0R, Malling\u00a0HJ (1998) Allergen immunotherapy: therapeutic vaccines for allergic diseases. A\u00a0WHO position paper. J\u00a0Allergy Clin Immunol 102:558\u2013562. https:\/\/doi.org\/10.1016\/s0091-6749(98)70271-4","journal-title":"J Allergy Clin Immunol"},{"key":"5400_CR4","doi-asserted-by":"publisher","first-page":"101534","DOI":"10.1016\/j.arr.2021.101534","volume":"73","author":"N Veronese","year":"2022","unstructured":"Veronese\u00a0N, Demurtas\u00a0J, Smith\u00a0L et\u00a0al (2022) Influenza vaccination reduces dementia risk: A\u00a0systematic review and meta-analysis. Ageing Res Rev 73:101534. https:\/\/doi.org\/10.1016\/j.arr.2021.101534","journal-title":"Ageing Res Rev"},{"key":"5400_CR5","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.21873\/invivo.12622","volume":"35","author":"S Lehrer","year":"2021","unstructured":"Lehrer\u00a0S, Rheinstein\u00a0PH (2021) Herpes Zoster Vaccination Reduces Risk of Dementia. In Vivo 35:3271\u20133275. https:\/\/doi.org\/10.21873\/invivo.12622","journal-title":"In Vivo"},{"key":"5400_CR6","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","volume":"4","author":"JW Kinney","year":"2018","unstructured":"Kinney\u00a0JW, Bemiller\u00a0SM, Murtishaw\u00a0AS et\u00a0al (2018) Inflammation as a\u00a0central mechanism in Alzheimer\u2019s disease. Alzheimers Dement 4:575\u2013590. https:\/\/doi.org\/10.1016\/j.trci.2018.06.014","journal-title":"Alzheimers Dement"},{"key":"5400_CR7","doi-asserted-by":"publisher","first-page":"e228873","DOI":"10.1001\/jamanetworkopen.2022.8873","volume":"5","author":"B Behrouzi","year":"2022","unstructured":"Behrouzi\u00a0B, Bhatt\u00a0DL, Cannon\u00a0CP et\u00a0al (2022) Association of Influenza Vaccination With Cardiovascular Risk: A\u00a0Meta-analysis. JAMA Netw Open 5:e228873. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.8873","journal-title":"JAMA Netw Open"},{"key":"5400_CR8","doi-asserted-by":"publisher","first-page":"e914","DOI":"10.1016\/S2468-2667(22)00222-5","volume":"7","author":"JK Holodinsky","year":"2022","unstructured":"Holodinsky\u00a0JK, Zerna\u00a0C, Malo\u00a0S et\u00a0al (2022) Association between influenza vaccination and risk of stroke in Alberta, Canada: a\u00a0population-based study. Lancet Public Health 7:e914\u2013e922. https:\/\/doi.org\/10.1016\/S2468-2667(22)00222-5","journal-title":"Lancet Public Health"},{"key":"5400_CR9","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1001\/jama.2022.12992","volume":"328","author":"YE Kim","year":"2022","unstructured":"Kim\u00a0YE, Huh\u00a0K, Park\u00a0YJ et\u00a0al (2022) Association Between Vaccination and Acute Myocardial Infarction and Ischemic Stroke After COVID-19 Infection. JAMA 328:887\u2013889. https:\/\/doi.org\/10.1001\/jama.2022.12992","journal-title":"JAMA"},{"key":"5400_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8040547","author":"PH Wu","year":"2019","unstructured":"Wu\u00a0PH, Chuang\u00a0YS, Lin\u00a0YT (2019) Does Herpes Zoster Increase the Risk of Stroke and Myocardial Infarction? A\u00a0Comprehensive Review. J\u00a0Clin Med. https:\/\/doi.org\/10.3390\/jcm8040547","journal-title":"J Clin Med"},{"key":"5400_CR11","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1038\/s41598-023-29667-w","volume":"13","author":"A Horev","year":"2023","unstructured":"Horev\u00a0A, Horev\u00a0A, Gordon-Irshai\u00a0A et\u00a0al (2023) Herpes zoster and long-term vascular risk: a\u00a0retrospective cohort study. Sci Rep 13:2364. https:\/\/doi.org\/10.1038\/s41598-023-29667-w","journal-title":"Sci Rep"},{"key":"5400_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.amjmed.2022.11.002","volume":"136","author":"DA Redelmeier","year":"2023","unstructured":"Redelmeier\u00a0DA, Wang\u00a0J, Thiruchelvam\u00a0D (2023) COVID Vaccine Hesitancy and Risk of a\u00a0Traffic Crash. Am J Med 136:153\u2013162. https:\/\/doi.org\/10.1016\/j.amjmed.2022.11.002 (e155)","journal-title":"Am J Med"},{"key":"5400_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/pch\/pxy011","volume":"23","author":"D Scheifele","year":"2018","unstructured":"Scheifele\u00a0D, Ward\u00a0B (2018) Fever prophylaxis can reduce vaccine responses: A\u00a0caution. Paediatr Child Health 23:245\u2013246. https:\/\/doi.org\/10.1093\/pch\/pxy011","journal-title":"Paediatr Child Health"},{"key":"5400_CR14","first-page":"18","volume":"2022","author":"Robert Koch Institut","year":"2022","unstructured":"Robert Koch Institut (2022) Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) beim Robert Koch-Institut. Epidemiol Bull 4\/2022: 18\u201319","journal-title":"Epidemiol Bull"},{"key":"5400_CR15","doi-asserted-by":"publisher","first-page":"S429","DOI":"10.1093\/infdis\/jiab387","volume":"224","author":"R Harbecke","year":"2021","unstructured":"Harbecke\u00a0R, Cohen\u00a0JI, Oxman\u00a0MN (2021) Herpes Zoster Vaccines. J\u00a0Infect Dis 224:S429\u2013S442. https:\/\/doi.org\/10.1093\/infdis\/jiab387","journal-title":"J Infect Dis"},{"issue":"4","key":"5400_CR16","first-page":"06","volume":"2023","author":"Robert Koch Institut","year":"2023","unstructured":"Robert Koch Institut (2023) Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) beim Robert Koch-Institut. Epidemiol Bull 4\/2023:6\u201315","journal-title":"Epidemiol Bull"},{"key":"5400_CR17","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s00103-019-02905-1","volume":"62","author":"N Wagner","year":"2019","unstructured":"Wagner\u00a0N, Assmus\u00a0F, Arendt\u00a0G et\u00a0al (2019) Impfen bei Immundefizienz \u2013 Anwendungshinweise zu den von der St\u00e4ndigen Impfkommission empfohlenen Impfungen. (IV)\u00a0Impfen bei Autoimmunkrankheiten, bei anderen chronisch-entz\u00fcndlichen Erkrankungen und unter immunmodulatorischer Therapie. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 62:494\u2013515. https:\/\/doi.org\/10.1007\/s00103-019-02905-1","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"5400_CR18","unstructured":"Koch J, Vygen-Bonnet S, Bogdan C et al (2022) Wissenschaftliche Begr\u00fcndung zur COVID-19-Impfempfehlung der STIKO f\u00fcr Personen mit durchgemachter SARS-CoV-2-Infektion und bisher unvollst\u00e4ndiger Immunit\u00e4t. Epidemiol Bull 21\/2022: 44\u201351"},{"key":"5400_CR19","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/ddg.14156_g","volume":"18","author":"S Mohme","year":"2020","unstructured":"Mohme\u00a0S, Schmalzing\u00a0M, M\u00fcller\u00a0CSL et\u00a0al (2020) Impfen bei Immunsuppression: ein Leitfaden f\u00fcr die dermatologische Praxis. JDDG: J Dtsch Dermatologischen Ges 18:699\u2013725. https:\/\/doi.org\/10.1111\/ddg.14156_g","journal-title":"JDDG: J Dtsch Dermatologischen Ges"},{"issue":"46","key":"5400_CR20","first-page":"15","volume":"2022","author":"Robert Koch Institut","year":"2022","unstructured":"Robert Koch Institut (2022) Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) beim Robert Koch-Institut. Epidemiol Bull 46\/2022:15\u201318","journal-title":"Epidemiol Bull"},{"key":"5400_CR21","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1136\/annrheumdis-2021-221244","volume":"80","author":"MA Friedman","year":"2021","unstructured":"Friedman\u00a0MA, Curtis\u00a0JR, Winthrop\u00a0KL (2021) Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis 80:1255\u20131265. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221244","journal-title":"Ann Rheum Dis"},{"key":"5400_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/cid\/ciz202","volume":"70","author":"CR Chong","year":"2020","unstructured":"Chong\u00a0CR, Park\u00a0VJ, Cohen\u00a0B et\u00a0al (2020) Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors. Clin Infect Dis 70:193\u2013199. https:\/\/doi.org\/10.1093\/cid\/ciz202","journal-title":"Clin Infect Dis"},{"key":"5400_CR23","unstructured":"Robert Koch-Institut Affenpocken: Kontaktpersonenmanagement. https:\/\/www.rki.de\/DE\/Content\/InfAZ\/A\/Affenpocken\/Kontaktpersonen.html. Zugegriffen: 17. Juni 2024"},{"key":"5400_CR24","unstructured":"Robert Koch-Institut STIKO-Empfehlung zur 2. Auffrischimpfung gegen COVID-19. https:\/\/www.rki.de\/DE\/Content\/Kommissionen\/STIKO\/Empfehlungen\/PM_2022-06-09.html. Zugegriffen: 17. Juni 2024"},{"key":"5400_CR25","volume-title":"WHO Director-General declares mpox outbreak a public health emergency of international concern","author":"World Health Organization","year":"2024","unstructured":"World Health Organization (2024) WHO Director-General declares mpox outbreak a public health emergency of international concern. https:\/\/www.who.int\/news\/item\/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern. Zugegriffen: 18. Aug. 2024"},{"key":"5400_CR26","first-page":"2517","volume":"98","author":"A Schneider","year":"2001","unstructured":"Schneider\u00a0A, Hoyer\u00a0H, Durst\u00a0M (2001) Bedeutung des Nachweises von humanen Papillomviren fur die Vorsorge. Dtsch Arzteblatt-arztliche Mitteilungen-ausgabe\u00a0A 98:2517\u20132520","journal-title":"Dtsch Arzteblatt-arztliche Mitteilungen-ausgabe A"},{"key":"5400_CR27","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/j.1365-2133.2010.09712.x","volume":"162","author":"A Kreuter","year":"2010","unstructured":"Kreuter\u00a0A, Potthoff\u00a0A, Brockmeyer\u00a0NH et\u00a0al (2010) Anal carcinoma in human immunodeficiency virus-positive men: results of a\u00a0prospective study from Germany. Br J Dermatol 162:1269\u20131277. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.09712.x","journal-title":"Br J Dermatol"},{"key":"5400_CR28","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","volume":"383","author":"J Lei","year":"2020","unstructured":"Lei\u00a0J, Ploner\u00a0A, Elfstrom\u00a0KM et\u00a0al (2020) HPV Vaccination and the Risk of Invasive Cervical Cancer. N\u00a0Engl J Med 383:1340\u20131348. https:\/\/doi.org\/10.1056\/NEJMoa1917338","journal-title":"N Engl J Med"},{"key":"5400_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9050410","author":"V Di Donato","year":"2021","unstructured":"Di Donato\u00a0V, Caruso\u00a0G, Petrillo\u00a0M et\u00a0al (2021) Adjuvant HPV Vaccination to Prevent Recurrent Cervical Dysplasia after Surgical Treatment: A\u00a0Meta-Analysis. Vaccines. https:\/\/doi.org\/10.3390\/vaccines9050410","journal-title":"Vaccines"},{"key":"5400_CR30","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jaad.2019.04.067","volume":"82","author":"CT Pham","year":"2020","unstructured":"Pham\u00a0CT, Juhasz\u00a0M, Sung\u00a0CT et\u00a0al (2020) The human papillomavirus vaccine as a\u00a0treatment for human papillomavirus-related dysplastic and neoplastic conditions: A\u00a0literature review. J\u00a0Am Acad Dermatol 82:202\u2013212. https:\/\/doi.org\/10.1016\/j.jaad.2019.04.067","journal-title":"J Am Acad Dermatol"},{"key":"5400_CR31","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jaad.2021.03.074","volume":"86","author":"JO Shin","year":"2022","unstructured":"Shin\u00a0JO, Son\u00a0JH, Lee\u00a0J et\u00a0al (2022) Nonavalent human papilloma virus vaccine for the treatment of multiple recalcitrant warts: An open-label study. J\u00a0Am Acad Dermatol 86:940\u2013941. https:\/\/doi.org\/10.1016\/j.jaad.2021.03.074","journal-title":"J Am Acad Dermatol"},{"key":"5400_CR32","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1097\/DSS.0000000000001867","volume":"45","author":"A Waldman","year":"2019","unstructured":"Waldman\u00a0A, Whiting\u00a0D, Rani\u00a0M et\u00a0al (2019) HPV Vaccine for Treatment of Recalcitrant Cutaneous Warts in Adults: A\u00a0Retrospective Cohort Study. Dermatol Surg 45:1739\u20131741. https:\/\/doi.org\/10.1097\/DSS.0000000000001867","journal-title":"Dermatol Surg"},{"key":"5400_CR33","doi-asserted-by":"publisher","first-page":"798927","DOI":"10.3389\/fmicb.2021.798927","volume":"12","author":"R Krishnan","year":"2021","unstructured":"Krishnan\u00a0R, Stuart\u00a0PM (2021) Developments in Vaccination for Herpes Simplex Virus. Front Microbiol 12:798927. https:\/\/doi.org\/10.3389\/fmicb.2021.798927","journal-title":"Front Microbiol"},{"key":"5400_CR34","volume-title":"A\u00a0Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a\u00a0Targeted Immunotherapy Against HSV in Healthy Participants Aged 18\u201340 Years or in Participants Aged 18\u201360 Years With Recurrent Genital Herpes","author":"GlaxoSmithKline","year":"2024","unstructured":"GlaxoSmithKline (2024) A\u00a0Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a\u00a0Targeted Immunotherapy Against HSV in Healthy Participants Aged 18\u201340 Years or in Participants Aged 18\u201360 Years With Recurrent Genital Herpes (https:\/\/classic.clinicaltrials.gov\/show\/NCT05298254)"},{"key":"5400_CR35","doi-asserted-by":"publisher","first-page":"644664","DOI":"10.3389\/fimmu.2021.644664","volume":"12","author":"AL Verzosa","year":"2021","unstructured":"Verzosa\u00a0AL, McGeever\u00a0LA, Bhark\u00a0SJ et\u00a0al (2021) Herpes Simplex Virus 1 Infection of Neuronal and Non-Neuronal Cells Elicits Specific Innate Immune Responses and Immune Evasion Mechanisms. Front Immunol 12:644664. https:\/\/doi.org\/10.3389\/fimmu.2021.644664","journal-title":"Front Immunol"},{"key":"5400_CR36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.pt.2010.06.006","volume":"27","author":"TJ Schuijt","year":"2011","unstructured":"Schuijt\u00a0TJ, Hovius\u00a0JW, van der Poll\u00a0T et\u00a0al (2011) Lyme borreliosis vaccination: the facts, the challenge, the future. Trends Parasitol 27:40\u201347. https:\/\/doi.org\/10.1016\/j.pt.2010.06.006","journal-title":"Trends Parasitol"},{"key":"5400_CR37","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/S1473-3099(23)00210-4","volume":"23","author":"N B\u00e9zay","year":"2023","unstructured":"B\u00e9zay\u00a0N, Hochreiter\u00a0R, Kadlecek\u00a0V et\u00a0al (2023) Safety and immunogenicity of a\u00a0novel multivalent OspA-based vaccine candidate against Lyme borreliosis: a\u00a0randomised, phase\u00a01\u00a0study in healthy adults. Lancet Infect Dis 23:1186\u20131196","journal-title":"Lancet Infect Dis"},{"key":"5400_CR38","unstructured":"Pfizer (2023) An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15). https:\/\/classic.clinicaltrials.gov\/show\/NCT05477524"},{"key":"5400_CR39","unstructured":"Pfizer VAG (2022) Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population. https:\/\/classic.clinicaltrials.gov\/show\/NCT04801420"},{"key":"5400_CR40","doi-asserted-by":"publisher","first-page":"1126170","DOI":"10.3389\/fimmu.2023.1126170","volume":"14","author":"C Avila-Nieto","year":"2023","unstructured":"Avila-Nieto\u00a0C, Pedreno-Lopez\u00a0N, Mitja\u00a0O et\u00a0al (2023) Syphilis vaccine: challenges, controversies and opportunities. Front Immunol 14:1126170. https:\/\/doi.org\/10.3389\/fimmu.2023.1126170","journal-title":"Front Immunol"},{"key":"5400_CR41","unstructured":"GlaxoSmithKline (2024) Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age. https:\/\/classic.clinicaltrials.gov\/show\/NCT05630859"},{"key":"5400_CR42","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40425-018-0345-7","volume":"6","author":"M Lattanzi","year":"2018","unstructured":"Lattanzi\u00a0M, Han\u00a0J, Moran\u00a0U et\u00a0al (2018) Adjuvant NY-ESO\u20111 vaccine immunotherapy in high-risk resected melanoma: a\u00a0retrospective cohort analysis. J\u00a0Immunother Cancer 6:38. https:\/\/doi.org\/10.1186\/s40425-018-0345-7","journal-title":"J Immunother Cancer"},{"key":"5400_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000410","author":"JS Cebon","year":"2020","unstructured":"Cebon\u00a0JS, Gore\u00a0M, Thompson\u00a0JF et\u00a0al (2020) Results of a\u00a0randomized, double-blind phase\u00a0II clinical trial of NY-ESO\u20111 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. J\u00a0Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2019-000410","journal-title":"J Immunother Cancer"},{"key":"5400_CR44","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03400-y","author":"N Dasyam","year":"2023","unstructured":"Dasyam\u00a0N, Sharples\u00a0KJ, Barrow\u00a0C et\u00a0al (2023) A\u00a0randomised controlled trial of long NY-ESO\u20111 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma. Cancer Immunol Immunother. https:\/\/doi.org\/10.1007\/s00262-023-03400-y","journal-title":"Cancer Immunol Immunother"},{"key":"5400_CR45","doi-asserted-by":"publisher","first-page":"LBA9503\u2013LBA9503","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA9503","volume":"41","author":"A Khattak","year":"2023","unstructured":"Khattak\u00a0A, Weber\u00a0JS, Meniawy\u00a0T et\u00a0al (2023) Distant metastasis-free survival results from the randomized, phase\u00a02 mRNA-4157-P201\/KEYNOTE-942 trial. JCO 41:LBA9503\u2013LBA9503. https:\/\/doi.org\/10.1200\/JCO.2023.41.17_suppl.LBA9503","journal-title":"JCO"},{"key":"5400_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11030636","author":"D Bafaloukos","year":"2023","unstructured":"Bafaloukos\u00a0D, Gazouli\u00a0I, Koutserimpas\u00a0C et\u00a0al (2023) Evolution and Progress of mRNA Vaccines in the Treatment of Melanoma: Future Prospects. Vaccines. https:\/\/doi.org\/10.3390\/vaccines11030636","journal-title":"Vaccines"},{"key":"5400_CR47","unstructured":"Biontech (2024) Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory\/Relapsed, Unresectable Stage III or IV Melanoma. https:\/\/classic.clinicaltrials.gov\/show\/NCT04526899"},{"key":"5400_CR48","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4103\/idoj.idoj_449_22","volume":"14","author":"A Mohta","year":"2023","unstructured":"Mohta\u00a0A, Nyati\u00a0A, Mohta\u00a0A et\u00a0al (2023) Histopathological Spectrum of Cutaneous Reactions following COVID-19 Vaccine\u2014An Observational Study. Indian Dermatol Online\u00a0J 14:207\u2013212. https:\/\/doi.org\/10.4103\/idoj.idoj_449_22","journal-title":"Indian Dermatol Online J"},{"key":"5400_CR49","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1542\/peds.112.4.815","volume":"112","author":"K Bohlke","year":"2003","unstructured":"Bohlke\u00a0K, Davis\u00a0RL, Marcy\u00a0SM et\u00a0al (2003) Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 112:815\u2013820. https:\/\/doi.org\/10.1542\/peds.112.4.815","journal-title":"Pediatrics"},{"key":"5400_CR50","doi-asserted-by":"publisher","unstructured":"Schmidt S (2018) Impfen: Was tun bei bestehenden Allergien? Deutsches \u00c4rzteblatt Online https:\/\/doi.org\/10.3238\/PersPneumo.2018.03.09.01","DOI":"10.3238\/PersPneumo.2018.03.09.01"},{"key":"5400_CR51","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/jdv.17744","volume":"36","author":"T Gambichler","year":"2022","unstructured":"Gambichler\u00a0T, Boms\u00a0S, Susok\u00a0L et\u00a0al (2022) Cutaneous findings following COVID-19 vaccination: review of world literature and own experience. J\u00a0Eur Acad Dermatol Venereol 36:172\u2013180. https:\/\/doi.org\/10.1111\/jdv.17744","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5400_CR52","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12879-022-07973-4","volume":"23","author":"M Agustin","year":"2023","unstructured":"Agustin\u00a0M, Trifitriana\u00a0M, Danarti\u00a0R (2023) COVID arm as a\u00a0common cutaneous manifestation after mRNA-1273 vaccination: a\u00a0systematic review. BMC Infect Dis 23:7. https:\/\/doi.org\/10.1186\/s12879-022-07973-4","journal-title":"BMC Infect Dis"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05400-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-024-05400-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05400-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T08:09:29Z","timestamp":1730794169000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-024-05400-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["5400"],"URL":"https:\/\/doi.org\/10.1007\/s00105-024-05400-0","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]},"assertion":[{"value":"9 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>S.\u00a0Schrenker<\/b>: A.\u00a0Finanzielle Interessen: S.\u00a0Schrenker gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Seit 01\/2024: Angestellter Arzt in Weiterbildung in Hautarztpraxis Dr. Thomas Schrenker\u00a0\u2013 Bielefeld; bis 12\/2023: Angestellter Arzt am Uniklinikum M\u00fcnster Hautklinik. <b>L.\u00a0Erpenbeck<\/b>: A.\u00a0Finanzielle Interessen: L.\u00a0Erpenbeck gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B. Nichtfinanzielle Interessen: Angestellte Dermatologin, Klinik f\u00fcr Hautkrankheiten, UKM, Universit\u00e4t M\u00fcnster, M\u00fcnster | Mitgliedschaften: Arbeitsgemeinschaft Dermatologische Forschung (ADF, hier auch Vorstandsmitglied), Arbeitsgemeinschaft Dermatohistologie (ADH), Deutsche Dermatologische Gesellschaft (DDG).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}